Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) EPS (Weighted Average and Diluted) (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.12 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 80.0% year-over-year to -$0.12; the TTM value through Sep 2025 reached -$0.98, down 6.52%, while the annual FY2023 figure was -$0.56, 37.08% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.12 in Q3 2025 per CRVS's latest filing, up from -$0.13 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.07 in Q2 2024 and bottomed at -$0.6 in Q3 2024.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.19, with a median of -$0.14 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 400.0% in 2024, then soared 80.0% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.21 in 2022, then skyrocketed by 38.1% to -$0.13 in 2023, then crashed by 361.54% to -$0.6 in 2024, then skyrocketed by 80.0% to -$0.12 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.12 in Q3 2025, -$0.13 in Q2 2025, and -$0.13 in Q1 2025.